PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Mesoblast, Inc.
A PHASE2 clinical study on Chronic Bronchitis and Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Mesoblast, Inc. and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Mar 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mesoblast, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .